X

Drug Profile

VR 101

Alternative Names: long-acting progestin - VaRi Bioscience; VR-101

Latest Information Update: 13 Feb 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VaRi Bioscience
Class Hormonal contraceptives; Progesterone congeners
Mechanism of Action Progesterone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Pregnancy

Most Recent Events

06 Feb 2023 VaRi Bioscience files for patent protection with European Patent Office for innovative formulation concepts of VR 101 in Europe (VaRi Bioscience website, February 2023)
06 Feb 2023 Phase-II clinical trials in Pregnancy (Prevention) in Germany (Vaginal, Ring) before February 2023 (VaRi Bioscience pipeline, February 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com